Approved for use through 07/31/2006. OMB 0651-0032 U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE SUBSTITUTE for PTO/SB/17(10-03)"FEE TRANSMITTAL for FY 2004"

		Con	nplete if Known
FEE TRANSMITTAL		Application Number	09/835,694
\		Filing Date	April 16, 2001
		First Named Inventor	Donnelly et al.
Patent fees are subject to annual revision.	1.	Examiner Name	Garvey, Tara L.
/		Group Art Unit	1636
AL AMOUNT OF PAYMENT	\$180	Attorney Docket Number	18972PCA

METHOD OF PAYN	MENT	FEE CALCULATION (continued)			
Deposit Account		3. ADDITIONAL FEES			
Deposit Account Number Deposit Account Name 13-2		Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
Name Merck &	Co., Inc.	1051	130	Surcharge - late filing fee or oath	
The Director is authorized to:		1053	130	Non-English specification	
Charge fee(s) indicated below	Credit any overpayments	1812	2,520	For filing a request for ex parte reexamination	
Charge any additional fee(s) during	the pendency of this	1251	110	Extension for reply within first month	
application		1252	430	Extension for reply within second month	
FEE CALCULAT	ION	1253	980	Extension for reply within third month	
1. BASIC FILING FEE		1254	1,530	Extension for reply within fourth month	
Large Entity Fee Fee Fee Description	Fee Paid	1255	2,080	Extension for reply within fifth month	
Code (\$)		1401	340	Notice of Appeal	
1001 790 Utility filing fee		1402	340	Filing a brief in support of an appeal	
1002 350 Design filing fee		1403	300	Request for oral hearing	
1004 790 Reissue filing fee		1452	110	Petition to revive - unavoidable	
1005 160 Provisional filing fee		1453	1,370	Petition to revive - unintentional	
SUBTOTAL	L(1) \$0	1501	1,370	Utility issue fee (or reissue)	
		1502	490	Design issue fee	
2. EXTRA CLAIM FEES Ex	tra Fee from Fee Paid	1460	130	Petitions to the Commissioner	
Total Claims - 20 ** =	0 x \$18 = 0	1807	50	Processing fee under 37 CFR 1.17(q)	
Independent Claims - 3 ** =	$0 \times $88 = 0$	1806	180	Submission of Information Disclosure Statement	180
Multiple Dependent Claims	\$300 =	8021	40	Recording each patent assignment per property (times number of properties)	
**or number previously paid, if greater; For Large Entity Fee Fee Fee Description	·	1809	790	Filing a submission after final rejection (37 CFR 1.129(a))	
Code (\$) 1202 18 Claims in excess of 2	0	1810	790	For each additional invention to be examined (37 CFR 1.129(b))	
1201 88 Independent claims in	excess of 3	1801	790	Request for Continued Examination	
1203 300 Multiple dependent cl	aim, if not paid			(RCE)	
1204 88 **Reissue independer	at claims over original patent	Other fo	ee (speci	fy) ————————————————————————————————————	
1205 18 **Reissue claims in e.	xcess of 20 and over original	Other fo	ee (speci	fy)	
SUBTOTAL	.(2) \$0			SUBTOTAL(3)	\$180

	SUBMITTED BY	Comp	lete (if applicable)		
Typed or Printed Name	J. Mark Hand			Reg. Number	36,545
Signature	9. Marfail	Date	12/10/04	Deposit Account User ID	

DE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Donnelly et al.	OIPE
Serial No.	0 9 /835,694	DEC 1 3 2004
Filed: April	16, 2001	The waster

For: NUCLEIC ACID VACCINES AGAINST HUMAN

101.	INFLUENZA VIRUS
	ecionar for Patents

Art Unit:	1636	

Examiner: Garvey, Tara L.

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

12/15/2004 GWDRDDF1 00000044 132755 09835694 02 FC:1806 180.00 DA I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

J. Martanl Date 12/10/04

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION			
FILING DATE	MERCK CASE		
	-		

If this is inconvenient, additional copies will be submitted upon request.

	6. In accordance with 37 C.F.R. 1.97, (check one)
	the attached information is filed within three months of the filing date of the captioned case.
	the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
\checkmark	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p)
	the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
	the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.
	Respectfully submitted,

By: J. Mark Hand

Attorney For Applicant(s)

Reg. No. 36545

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3905

Date: December 10, 2004



Šu	Substitute for form 1449A/PTO		COMPLETE IF KNOWN				
INFORMATION DISCLOSURE				Application Number	09/835,694		
C	STATEMENT BY APPLICANT		Filing Date	April 16, 2001			
STATEMENT BY APPLICANT		First Named Inventor	J.J. Donnelly				
				Group Art Unit	1636		
	(use as many sheets as necessary)		Examiner Name	Garvey, Tara L.			
heet	1	of	8	Attorney Docket Number	18972PCA		

		U.	S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	(ind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A	3,931,397		Harnden	01/06/1976
-	В	4,806,463		Goodchild et al.	02/21/1989
	С	4,224,404		Viza et al.	09/23/1980
	D	4,394,448		Szoka et al.	07/19/1983
	Е	4,689,320 DEC 5,589,466 FADENCE TRADENCE TRADENC		Kaji	08/25/1987
	F	5,589,466		Felgner	12/31/1996
	G	5,316,910 TRADE		Rota	05/31/1994
*					

			FORE	IGN PATENT	T DOCUMENTS	
Examiner	Cite	Foreign Patent Document Cite Kind		Name of Patentee or Applicant	Date of Publication of Cited Document	
nitials*	No.	Office	Number	Code (if known)	of Cited Document	MM-DD-YYYY
	Н	PCT	WO90/11092		Vical, Inc	10/04/1990
	I	PCT	WO86/00930		Worcester Foundation for Experimental Biology	02/13/1986
	J	PCT	WO94/06468		SmithKline Beecham Corp	03/31/1994
	K	PCT	WO93/15763		SmithKline Beecham Corp	08/19/1993
	L	PCT	WO93/12756		The Regents of the Univ of California	07/08/1993
	M	PCT	WO93/12240		The Regents of the Univ of California	06/24/1993
	N	PCT	WO93/03709		Vical Inc.	03/04/1993
	0	PCT	WO91/17424		Vical Inc.	11/14/1991
	P	PCT	WO91/16024		Vical Inc.	11/13/1991
	Q	PCT	WO90/01543		Intracel Corp.	02/22/1990

Examiner Signature	 	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

					Tatch and Transfer Office, 0.3 Del ARTIMENT OF COMMERCE		
·s	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN			
]	INFORMATION 1	DIS	CLOSURE	Application Number	09/835,694		
c	STATEMENT BY	AT	DI ICANT	Filing Date	April 16, 2001		
2	SIAIEWENI DI	AF	PLICANI	First Named Inventor	J.J. Donnelly		
			,	Group Art Unit	1636		
	(use as many sheets	as n	necessary)	Examiner Name	Garvey, Tara L.		
Sheet	1A	of	8	Attorney Docket Number	18972PCA		

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Docum Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
			·					

			FORE	IGN PATENT I	OCUMENTS	
			Foreign Patent Docume	ent		Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
	R	PCT	WO93/19183			09/30/1993
	S	JР	63-304988			12/13/1988
	Т	JР	63-283578			
	U	JР	62-51992			
	V	JР	7-507203			08/10/1995

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ı. Sı	ubstitute for form 1449B/PTO				COMPLETE IF KNOWN
	NFORMATION	DIS	CLOSURE	Application Number	09/835,694
C		K7 A T		Filing Date	April 16, 2001
3	TATEMENT B	Y AP	PLICANI	First Named Inventor	J.J. Donnelly
				Group Art Unit	1636
	(use as many shee	ts as r	necessary)	Examiner Name	Garvey, Tara L.
Sheet	2	of	8	Attorney Docket Number	18972PCA

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Wang et al., 'Genetic Immunization: A Novel Method for Vaccine Development Against HIV', Modern Approaches to New Vaccines, Including Prevention of Aids', p. 99 (9/16-9/29/92)
	AB	Liu et al. 'Immunization with DNA Encoding a Conserved Inter nal Viral' Modern Approaches to New Vaccines, Including Prevention of Aids, p. 98 (9/16-9/29/92)
	AC	Rhodes et al., 'A Novel Method of Inducing Cellular and Humoral Immunity' Moderan Approaches to New Vaccines, Including Prevention of Aids', p. 91 (9/16-9/29/92)
	AD	Donnelly et al., 'Immunization with Influenza a Nucleoprotein' Modern Approaches to New Vaccines, Including Prevention of Aids', p. 23 (9/16-9/29/92)
	AE	Parker et al. 'Intramuscular Vaccination of Plasmid DNA Contianing', Modern Approaches to New Vaccines, Including Prevention of Aids', p. 47 (9/16-9/29/92)
	AF	Rhodes et al., 'Injection of Expression Vectors Contianing Antigen Genes', Modern Approaches to New Vaccines, Including Prevention of Aids', p. 51 (9/16-9/29/92)
·	AG	Friedman et al., 'Modulation of the Virulence of an H3N2 Influenza Virus', Modern Approaches to New Vaccines, Inclding Prevention of Aids, p. 68 (9/16-9/29/92)
-	АН	Edgington, S. 'PCR: Catching the Next Wave', Bio/Tech., 10: p 137-140 (1992)
	AI	Takahashi H., 'Induction of Broadly Cross-Reactive", Science, 255: p 333-336 (1992)
	AJ	Cudd & Nicolau, 'Intracellular Fate of Liposome", Biochimica et Biophysica Acta, 845, p 477-91 (1985)
	AK	Will et al., 'Infectious Hepatitis B Virus' Proc. Natl. Acad. Sci 82: p 891-895 (1985)
	AL	Feitelson, et al. ' A Chronic Carrierllike' J. of Virology, 62: No. 4, p 1408-1415 (1988)
	AM	Sureau et al. 'Cloned Hepatitis Delta" J. of Virology, 63: No. 10, p 4292-4297 (1989)
	AN	Seeger, et al. 'In Vitro Recombinants of Group', J. of Virology 61: No. 10, p 3241-3247 (1987)
	AO	Sprengel et al. 'Homologous Recombination between', virolog, 159: p 454-456 (1987)

Examiner Signature	Date Considered		

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

ŝ	ubstitute for form 1449B/PTO				COMPLETE IF KNOWN
I	NFORMATION 1	DIS	CLOSURE	Application Number	09/835,694
C		A TO	DI ICANIT	Filing Date	April 16, 2001
3	TATEMENT BY	AP	PLICANI	First Named Inventor	J.J. Donnelly
				Group Art Unit	1636
	(use as many sheets	as r	necessary)	Examiner Name	Garvey, Tara L.
Sheet	3	of	8	Attorney Docket Number	18972PCA

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
	AP	Sprengel et al. 'Cloned Duck Hepatitis B" J. of Virology, 52: No. 3, p 932-937 (1984)						
	AQ	Will et al., 'Cloned HBV DNA Causes Hepatitis', Nature, 299: p 740-742 (1982)						
	AR	Pestka et al. 'AntimRNA: Specific', Proc. Natl. Acad. Sci., 81: p 7525-7528 (1984)						
	AS	Dubensky et al. 'Direct Transfection of Viral' Pro. Natl. Acad. Sci., p 7529-7533 (1984)						
	АТ	Felgner, et al., 'Cationic liposome-mediated transfection' Nature, 337: No. 6205 p 387-388 (1989)						
	AU	Brigham et al. 'Rapid Communication: In Vivo Transfection', Am. J. Med. Sci., 298: p 278-281 (1989)						
	AV	Furth et al., 'Gene Transfer into Somatic' Analytical Biochem. 205: p. 365-368 (1992)						
	AW	Seeger et al. 'The Cloned Genome of Group Squirrel' Proc. Natl. acad. Sci., 81: p 5849-5852 (1984)						
	AX	Grosse et al. 'Flow Cytofluorometric Investigation of the Uptake', Bioch. et Biophysica Acta, 805: p 354-361 (1984)						
	AY	Wu and Wu, 'Receptor-mediated Gene Deliver' J. Bio. Chem. 263: NO. 29, p. 14621-14624 (1988)						
	ΑZ	Wang and Huang, 'pH Sensitive Immunoliposomes Mediate', Proc. Natl. Acad. Sci., 84: p7851-7855 (1987)						
	AAA	Nicolau et al., 'In vivo Expression of Rat Insulin' Proc. Natl. Acad. Sci. 80: p. 1068-1072 (1983)						
	AAB	Felgner, P.L. 'Particulate Systems and Polymers', Advanced Drug Delivery Reviews, 5: p. 1-25 (1990)						
	AAC	Nabel, et al. 'Site-Specific Gene Expression Vivo' Science, 249: p. 1285-1288 (1990)						
	AAD	Brigham et al. 'Expression of Prokaryotic Gene', Amer. J. Resp. Cell and Mol. Bio., 1: p. 95-100 (1989)						

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

, ,	ubstitute for form 1449B/PTO				COMPLETE IF KNOWN
	NFORMATION 1	DIS	CLOSURE	Application Number	09/835,694
C!	an a anternation for these	A TO	DI ICANIT	Filing Date	April 16, 2001
5	TATEMENT BY	AP	PLICANI	First Named Inventor	J.J. Donnelly
			,	Group Art Unit	1636
	(use as many sheets	as n	ecessary)	Examiner Name	Garvey, Tara L.
Sheet	4	of	8	Attorney Docket Number	18972PCA

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
	AAE	Holt, et al 'Lipofection of dDNAs in the Embryonic' Neuron. 4: p 203-214 (1990)					
	AAF	Tang et al. 'Genetic Immunization is aSimple' Nature, 356: p. 152-154 (1992)					
	AAG	Friedmann, T. 'Progress Toward Human Gene Therapy', Science 244: p. 1275-1281 (1989)					
	ААН	Felgner, et al. 'Lipofection: A highly efficient, lipid-mediated', Proc. Natl. Acad. Sci., 84: p. 7413-7417 (1987)					
	AAI	Wolff, et al. 'Direct Gene Transfer into Mouse' Science, 247: p. 1465-1468 (1990)					
	AAJ	Louis and Verma, 'An Alternative Approach to Somatic', Proc. Natl. Acad. Sci., 85: p. 3150-3154 (1988)					
	AAK	Malone et al. 'Cationic Liposome-mediated RNA Transfection', Proc. Natl. Acad. Sci., 86: p. 6077-6081 (1989)					
	AAL	Robinson et al. 'Use of Direct DNA Inoculations', Abst. of Papers Pres. at 1992 meeting, p. 91-92 (1992)					
	AAM	Physicians' Desk Ref., p. 1232-1234 (1993)					
	AAN	Marantz Henig, R., 'New Vaccine Method', NY Times Medical Science, pg C3 (1993)					
	AAO	'Genes in a Bottle', Bio/Technology, 10: p. 132-136 (1992)					
	AAP	Kaneda et al., 'Increased Expression of DNA', Science, 243: p. 375-378 (1989)					
	AAQ	Hansen et al. Strong Expression of Foreign Genes', FEBS, 290: p. 73-76 (1991)					
	AAR	Lin et al. 'Expression of Recombinant Genes' Circulation, 82: No. 6, p. 2217-2221 (1990)					
	AAS	Gammelin et al. 'Two Subtypes of Nucleoproteins' Virology, 170: p. 71-80 (1989)					

Examiner		Date	
a.			
Signature		Considered	
			1.

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

· ·	Substitute for form 1449B/PTO			COMPLETE IF KNOWN			
	INFORMATION DISCLOSURE			Application Number	09/835,694		
C	OD A ODDONACIONION IDNA	. A TI		Filing Date	April 16, 2001		
3	STATEMENT BY APPLICANT			First Named Inventor	J.J. Donnelly		
				Group Art Unit	1636		
	(use as many sheets	as n	ecessary)	Examiner Name	Garvey, Tara L.		
Sheet	5	of	8	Attorney Docket Number	18972PCA		

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
minus		Townsend and Bodmer, 'Antigen Recognition by Class I', Ann. Rev. Immunol. 7: p. 601-624 (1989)						
	AAU	Jiao et al., 'Direct Gene Transfer into Nonhuman' Human Gene Therapy, 3: p. 21-33 (1992)						
	AAV	Chapman et al. 'Effect of Intron A from Human Cytomegalovirus' Nucleic Acids Research, 19: No. 14, p. 3979-3986 (1991)						
	AAW	Yang et al., 'In Vivo and In Vitro Gene Transfer' Proc. Natl. Acad. sci. USA, 87: p. 9568-9572 (1990)						
	AAX	DeWet et al. 'Firefly Luciferase Gene: Structure', Molec. and Cell Biol. 7: No. 2, p . 725-737 (1987)						
	AAY	Johnston, S.A. 'Biolostic Transformation: Microbes to Mice', Mature 346: p. 776 (1990)						
	AAZ	Germain, R. 'The Ins and OUts of Antigen', Nature, 322: p. 687-689 (1986)						
	ABA	Bevan, M. 'Class Discrimination in the World of Immunology', Nature, 325: p. 192-194 (1987)						
	ABB	Acsadi, et al. 'Human Dystrophin Expression in MDX' Nature, 352, p. 815-818 (1991)						
	ABC	Giguere et al. 'Identification of a Receptor for the Morphofen Retinoic Acid', Nature, 330: p. 624-629 (1987)						
	ABD	Ono et al., 'Plasmid DNAs Directly Injected', Neuroscience Ltrs., 117: p. 259-263 (1990)						
	ABE	Whang et al., 'Expression of the Epstein-Bar Virus', J. of Virology, 61: No. 6, p. 1796-1807 (1987)						
	ABF	Gorman et al., 'Evolution of Influenza A Virus Nucleoprotein' J. of Virology, 65: No. 7, p. 3704-3714 (1991)						
	ABG	Wu et al., 'Targeting Genes: Delivery and Persistent Expression', The J. of Biol. Chem., 264: No. 29, p. 16985-16987 (1989)						
	АВН	Ulmer et al. 'Heterologous Protection Against Influenza', Science, 259: p. 1745-1749 (1993)						

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form *IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

· Sı	Substitute for form 1449B/PTO		COMPLETE IF KNOWN			
I	NFORMATION 1	DIS	CLOSURE	Application Number	09/835,694	
STATEMENT BY APPLICANT	DI ICANT	Filing Date	April 16, 2001			
3	STATEMENT BY APPLICANT			First Named Inventor	J.J. Donnelly	
				Group Art Unit	1636	
(use as many sheets as necessary)			ecessary)	Examiner Name	Garvey, Tara L.	
Sheet	6	of	8	Attorney Docket Number	18972PCA	

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.							
	ABI	Cohen, J., 'Naked DNA Points Way to Vaccines', Science, 259: p.1691-1692 (1993)							
	ABJ	Friend, T., 'Gene Therapy May Aid Heart Ailments', USA Today, p. 1-D, Feb. 11 (1991).							
	ABK	Soriano P., et al. 'Targeted and Nontargeted Liposomes', Proc. Natl. acad. Sci.: 80: p. 7128-7131 (1983)							
	ABL	1993 Conference, Washington, D.C. Bioeast, p. 57-58 Jan. 24-27 (1993)							
	ABM	Waldholz, M. 'Merck Team Develops a New Type', Wall Street Jour. Tech & Med. Section, March 19, (1993)							
	ABN	Wolff et al. 'Long-Term Persistance of Plasmid DNA', Human and Molec. Gen., 1: No. 6, p. 363-369 (1992)							
	АВО	Wolff and Lederberg, Human Gene Therapy, Vol. 5, pp. 469-480 (1994)							
	ABP	Yakubov, et al., 'Mechanism of Oligonucleotide Uptake by Cells', Proc. Natl. acad. sci, Vol. 86 pp. 6454-6458, (1989)							
	ABQ	Selden, et al., 'Expression of the Human Growth Hormone', Proc. Natl. Acad. Sci., Vol. 85, pp. 8241-8245 (1988)							
	ABR	Loyter et al., 'Mechanisms of DNA Uptake by Mammalian Cells', Proc. Natl. Acad. Sci., Vol. 79, pp. 422-426 (1982)							
	ABS	Chen et al. 'High-Efficiency Transofrmation of Mammalian Cells', Mol. cell. Biol., Vol 7, No. 8, 1987							
	ABT	Zhu et al. 'Systemic Gene Expression After Intravenious DNA', Science, Vo. 261, 1993							
	ABU	Wang, et al. 'Gene Inoculation Generates Immune Responses', Proc. Natl. Acad Sci., Vo. 90, pp 4156-4160, May 1993							
	ABV	Cheng et al. 'In Vivo Promoter Activity and Transgene Expression', Proc. Natl. acad. Sci., Vol 90, pp 4455-4459, 1993							
	ABW	Nicolau et al, 'Liposomes as Carriers for In Vivo Gene Transfer and Expression', Methods in Enzymology, Vol. 149, pp 157-177							

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
Substitute for form 1449B/PTO		COMPLETE IF KNOWN			
I	NFORMATION 1	DIS	CLOSURE	Application Number	09/835,694
STATEMENT BY APPLICANT	Filing Date	April 16, 2001			
3	STATEMENT BY APPLICANT			First Named Inventor	J.J. Donnelly
				Group Art Unit	1636
(use as many sheets as necessary)			ecessary)	Examiner Name	Garvey, Tara L.
Sheet	7	of	8	Attorney Docket Number	18972PCA

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
	ABX	Maninno et al., 'Liposome Mediated Gene transfer', Biotechniques, Vol. 6, No. 7, pp 682-690, 1988						
	ABY	Berton et al. 'Antigenic Structure of the Influenza B Virus Hemaglutinin;, J. of Vir., Vo 52, No. 3, pp 919-927, 1984						
	ABZ	Rota et al. 'Comparison of the Immune Response to Variant Influenza', Virology, Vol. 161, No. 2, pp 269-275, 1987						
	ACA	Rodriguez et al. 'Mammalian Expression Vectors, Vectors, pp 467-492, 1988						
	ACB	Physician's Desk Reference, 46th Ed., Medical Economics, NJ, pp 1204-1206, 1992						
	ACC	Brown et al., 'Assessment of Retrovirus-Expressed Nucleoprotein', Avian Diseases, Vol. 35, pp 515-520, 1992						
	ACD	Benvenisty and Reshef, 'Direct Introduction of Genes into Rats' Proc. Natl. Acad. Sci., 83: p 9551-9555 1986						
	ACE	Verma, I., 'Gene Therapy', Scientific American, p 68-84, 1990						
	ACF	Luckow and Schultz, 'Cat Constructions with Multiple Unique', Nucleic Acids Research, p. 5490, 1987						
	ACG	Kitsis, et al. 'Hormonal Modultion of a Gene Injected', Proc. Natl. Acad. sci. USA, 88: p. 4138-4142, 1991						
	АСН	Crystal, R.G., 'Transfer of Genes to Humans: Early Lessons and Obstacles to Success', Science, Vol. 270, pp 404-410, 1995						
	ACI	Rota et al. 'Comparison of inactivated, live and recombinant DNA vaccines against influenza virus in a mouse model', Virus Research, Vol. 16, pp 83-94, 1990						
	ACJ	Air et al. 'Conservation and Variation in Influenza Gene Sequences', UCLA Symp. Mol. Cell Biol., Vol. 21, pp 29-44, 1981						
	ACK	Whalen R.G. 'DNA Vaccines for Emerging Infectious Diseases: What if?', Emerging Infectious Diseases', Vol 2, No. 3, pp 168-175, July-Sept 1996						
L	<u> </u>	L						

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.